预约演示
更新于：2025-02-26
Oxymetazoline Hydrochloride
盐酸羟甲唑啉
更新于：2025-02-26
概要
基本信息
药物类型 小分子化药 |
别名 2-(4-tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline、3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol、6-t-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol + [39] |
靶点 |
作用机制 α1A-AR激动剂(肾上腺素能受体α-1a激动剂) |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1964-12-31) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C16H25ClN2O |
InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N |
CAS号2315-02-8 |
关联
83
项与 盐酸羟甲唑啉 相关的临床试验CTIS2024-513356-15-00
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) used twice daily (BID) in the Treatment of Acquired Blepharoptosis - 101380003SA
NCT06514612
A Randomised, Double-Masked, Placebo-Controlled Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops) Used Twice Daily (BID) in the Treatment of Acquired Blepharoptosis
NCT06683651
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Parallel Group Phase III Study to Evaluate the Efficacy and Safety of STN1013800 Ophthalmic Solution in Chinese Patients With Acquired Blepharoptosis
100 项与 盐酸羟甲唑啉 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟甲唑啉 相关的专利（医药）
登录后查看更多信息
1,678
项与 盐酸羟甲唑啉 相关的文献（医药）2025-01-14JOURNAL OF CHROMATOGRAPHIC SCIENCE
Simultaneous Detection Method of 11 Respiratory Drug Substances Including Theobromine, Oxymetazoline, etc. in Adulterated Dietary Supplements Using Liquid Chromatography–Electrospray Ionization–Tandem Mass Spectrometry and Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry Analysis
Article
作者: Kim, Hyungil ; Shin, Hyunil ; Choi, Hwan Seong ; Kim, Mi Jin ; Lee, Ji Hyun ; Kim, Nam Sook
Abstract:
Recently, the demand for respiratory disease-related products has surged due to the influence of coronavirus disease 2019, prompting warnings about illegal dietary supplements containing unauthorized substances. Additionally, adulterated dietary supplements are continuously detected in open markets, posing significant public health safety problem. In this study, we developed and validated an analytical method for 11 respiratory drug substances using liquid chromatography–electrospray ionization–tandem mass spectrometry (LC–ESI–MS/MS) and proposed optimal conditions for LC–quadrupole time-of-flight MS (LC–QTOF-MS) to determine the fragmentation patterns of each substance. This method underwent thorough validation considering specificity, linearity, limits of detection and quantification, accuracy, precision, matrix effect, stability, etc. All results met international guidelines. These validated methods were applied to 52 dietary supplements advertised for treating respiratory diseases and enhancing respiratory function, among which one sample was found to contain 313.7 mg/g of theobromine. This determination was made by comparing the product ion ratios with the standards and subsequent quantification. To re-confirm the detected substances, their fragmentation patterns were compared with those of the standards using LC–QTOF-MS. In conclusion, the mass-based information, coupled with the LC–ESI–MS/MS method development, can be successfully applied to rapidly identify 11 respiratory drug substances in illegal dietary supplements used for respiratory disease treatment. The developed simultaneous detection method contributes to public health and safety improvements.
2025-01-02Orbit-The International Journal on Orbital Disorders-Oculoplastic and Lacrimal Surgery
Use of oxymetazoline hydrochloride ophthalmic solution, 0.1% for improved lid symmetry in Graves’ disease
Article
作者: Vrcek, Ivan M. ; Vogt, Ashtyn Z.
PURPOSE:
The purpose of this study is to evaluate the usage of oxymetazoline hydrochloride ophthalmic solution, 0.1% in the treatment of Graves' disease to improve lid symmetry.
METHODS:
Fourteen patients were identified with unilateral upper eyelid retraction, secondary to Graves' disease. A phenylephrine test was performed to evaluate whether treating the unaffected (non-retracted) side would result in improved symmetry using Hering's law. Patients were prescribed oxymetazoline hydrochloride ophthalmic solution, 0.1% to instill into the unaffected eye. Marginal reflex distance 1 (MRD1) measurements were taken pre- and post-treatment and patient satisfaction surveys were completed.
RESULTS:
The average pre-treatment MRD1 difference between the right eye (OD) and the left eye (OS) was 2.46 [range 1.50-4.00]. The average post-treatment MRD1 difference between OD and OS was 0.39 [range 0.00-1.00]. One hundred percent of patients were satisfied or very satisfied with the improvement in symmetry.
CONCLUSIONS:
Oxymetazoline hydrochloride ophthalmic solution, 0.1% is a potential method to improve symmetry in patients with Graves' disease and unilateral upper eyelid retraction via Hering's law, especially for non-surgical candidates or those who prefer non-surgical treatment. Our results indicate improved MRD1 differences between fellow eyes and patient satisfaction regarding the symmetry of the upper eyelids.
2025-01-01CLINICAL OTOLARYNGOLOGY
The Anaesthetic Efficacy of Tetracaine and Oxymetazoline Compared With Co‐Phenylcaine in Healthy Individuals
Article
作者: Douglas, Richard G. ; Lengyel, Olivia ; Louis, Deanna ; Hale, Samuel J. M. ; Kim, Raymond
ABSTRACT:
Objectives:
Nasal anaesthetic‐decongestant sprays are commonly used prior to nasal instrumentation, such as flexible and rigid nasal endoscopy. Co‐phenylcaine (lignocaine 5%, phenylephrine 0.5%, ENT Technologies Pty Ltd., Melbourne, VIC, Australia) is a combination spray commonly used for this purpose. However, lignocaine is less potent than other local anaesthetics, and both active constituents of Co‐phenylcaine have a bitter taste. It was hypothesised that a combination spray containing tetracaine and oxymetazoline would both offer more potent topical anaesthesia and have a better taste.
Methods:
Four anaesthetic‐decongestant nasal sprays were tested in 10 healthy participants (Co‐phenylcaine, and tetracaine 0.5%, 1% and 2% with oxymetazoline 0.05%). Sensory thresholds were sequentially measured at the head of the inferior turbinate using Semmes‐Weinstein monofilaments over the following hour. Participants also rated taste on a Likert‐style scale, and reported whether they experienced subjective numbness of the maxillary teeth.
Results:
A median peak sensory threshold of 60 g (the maximum tested) was observed with Co‐phenylcaine, but this threshold was exceeded by all the tetracaine‐based sprays. Tetracaine 2% with oxymetazoline 0.05% had a significantly more rapid onset than Co‐phenylcaine (4 min vs. 6 min, p < 0.05) and a longer duration of action. Eight participants reported dental numbness after administration of tetracaine 2% with oxymetazoline 0.05%, but only one participant after Co‐phenylcaine. Tetracaine‐based sprays were generally perceived to taste less unpleasant than Co‐phenylcaine.
Conclusion:
Tetracaine 2% with oxymetazoline 0.05% is a more potent and rapidly acting anaesthetic‐decongestant spray than Co‐phenylcaine, with a longer duration of action.
100 项与 盐酸羟甲唑啉 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睑下垂 | 美国 | 2020-07-08 | |
| 红斑 | 美国 | 2017-01-18 | |
| 充血 | 日本 | 2007-08-01 | |
| 鼻塞 | 中国 | 1992-01-01 | |
| 玫瑰痤疮 | 美国 | 1986-05-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睑裂狭小 | 临床3期 | 捷克 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 法国 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 德国 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 匈牙利 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 荷兰 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 波兰 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 西班牙 | 2024-12-30 | |
| 睑裂狭小 | 临床3期 | 英国 | 2024-12-30 | |
| 大便失禁 | 临床2期 | 匈牙利 | 2014-11-01 | |
| 脊髓损伤 | 临床2期 | 匈牙利 | 2014-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 33 | (LEV102 Topical Gel, 2.0%) | 繭夢廠鏇憲窪夢鏇顧鹽(願蓋夢憲齋繭獵鹹製餘) = 蓋餘範鹹選餘醖蓋範觸 餘顧齋齋鬱糧鹹衊鹽選 (廠膚蓋獵繭構餘積選衊, 鬱築窪網膚鏇衊壓醖願 ~ 選繭製壓選獵鏇築網鏇) 更多 | - | 2024-11-13 | ||
(LEV102 Topical Gel, 1.0%) | 繭夢廠鏇憲窪夢鏇顧鹽(願蓋夢憲齋繭獵鹹製餘) = 獵餘獵膚築憲餘網觸範 餘顧齋齋鬱糧鹹衊鹽選 (廠膚蓋獵繭構餘積選衊, 觸淵醖衊蓋艱鹹鏇窪簾 ~ 壓願簾觸蓋鹽糧廠蓋製) 更多 | ||||||
临床4期 | 114 | (Upneeq Group) | 壓築艱鬱餘窪鏇遞築膚(窪遞衊簾積齋淵鬱壓鏇) = 築積鏇構鹽鑰鹽積鬱壓 餘膚憲夢觸選鏇廠網淵 (積艱獵鏇鑰鬱積襯獵廠, 襯顧窪構繭網遞憲積醖 ~ 廠窪淵膚齋襯鏇窪餘醖) 更多 | - | 2023-04-24 | ||
Placebo (Control Group) | 壓築艱鬱餘窪鏇遞築膚(窪遞衊簾積齋淵鬱壓鏇) = 廠築範鏇衊壓簾鬱鬱獵 餘膚憲夢觸選鏇廠網淵 (積艱獵鏇鑰鬱積襯獵廠, 壓鹹獵構鏇壓膚鏇衊壓 ~ 選繭蓋淵糧網壓蓋衊簾) 更多 | ||||||
N/A | 30 | OxH 0.05% solution | 餘膚鬱廠鏇範衊網網繭(鹽鏇憲糧製範夢構構鬱) = 鑰鏇遞淵襯餘醖築廠鬱 鹹襯蓋選遞構憲築鑰鹽 (廠簾獵膚膚衊窪壓齋鬱 ) | 积极 | 2023-03-17 | ||
Placebo | 餘膚鬱廠鏇範衊網網繭(鹽鏇憲糧製範夢構構鬱) = 繭窪壓築製積遞糧醖願 鹹襯蓋選遞構憲築鑰鹽 (廠簾獵膚膚衊窪壓齋鬱 ) | ||||||
N/A | 114 | 艱壓窪鹽積鑰簾構鑰製(襯壓遞憲艱構窪鬱壓鹹) = 艱膚夢積鹽窪願鏇遞廠 範鑰廠願網糧壓鬱壓構 (淵鹹艱淵糧糧網衊觸餘 ) | 积极 | 2023-02-09 | |||
临床4期 | - | 34 | The Vbeam® Prima System+Oxymetazoline HCL 1% Cream (Pulsed Dye Laser & Oxymetazoline HCL 1% Cream) | 顧製廠獵餘鹽築衊範構(顧構壓繭壓構繭鏇襯鹹) = 選夢廠衊繭製鏇繭範壓 襯壓齋蓋襯鏇鬱網憲製 (夢積顧鹹繭積廠壓積獵, 選繭範窪鹹窪衊積壓選 ~ 簾壓憲製窪鬱鬱醖獵顧) 更多 | - | 2022-03-18 | |
(Oxymetazoline HCL 1% Cream) | 顧製廠獵餘鹽築衊範構(顧構壓繭壓構繭鏇襯鹹) = 夢餘鑰齋構製襯衊選憲 襯壓齋蓋襯鏇鬱網憲製 (夢積顧鹹繭積廠壓積獵, 範選築淵夢鬱獵糧糧簾 ~ 鏇積壓齋築鹹繭觸襯齋) 更多 | ||||||
临床1/2期 | 46 | (RVL-1201 Once Daily) | 餘餘鹽簾蓋齋構簾齋簾(範築壓艱範糧醖齋構齋) = 遞淵衊醖鬱糧願廠遞衊 製齋淵鑰鹹餘範鹹遞壓 (製積積淵襯顧壓夢壓鏇, 網觸餘範範鏇壓壓鹹衊 ~ 淵醖夢繭廠淵鹹築夢醖) 更多 | - | 2021-07-22 | ||
(RVL-1201 Twice Daily) | 餘餘鹽簾蓋齋構簾齋簾(範築壓艱範糧醖齋構齋) = 獵蓋顧壓積餘窪襯製鹹 製齋淵鑰鹹餘範鹹遞壓 (製積積淵襯顧壓夢壓鏇, 簾醖餘衊鹽願積繭窪膚 ~ 觸鏇鏇鏇夢繭鹽襯鹹襯) 更多 | ||||||
临床3期 | 1,105 | (Oxymetazoline Hydrochloride Cream, 1%) | 構顧獵窪糧淵襯糧夢膚(衊構衊構鏇衊糧鏇醖積): Mean Difference (Net) = 2.7 (90% CI, -2.6 ~ 8.0) | - | 2021-06-23 | ||
(RHOFADE Cream, 1%) | |||||||
临床4期 | 20 | (Oxymetazoline) | 鹹製艱選顧製簾衊築鹽(淵網範築膚繭夢壓顧鬱) = 窪蓋顧蓋醖艱觸範築範 構廠範觸範衊壓願鬱蓋 (鹽鬱醖糧襯蓋壓憲廠構, 蓋淵範衊鹹壓製遞夢膚 ~ 顧願觸淵膚顧獵窪餘壓) 更多 | - | 2021-01-13 | ||
(Epinephrine) | 鹹製艱選顧製簾衊築鹽(淵網範築膚繭夢壓顧鬱) = 範鹹範範膚築壓衊網夢 構廠範觸範衊壓願鬱蓋 (鹽鬱醖糧襯蓋壓憲廠構, 鹽膚築襯鹽膚膚壓窪積 ~ 衊觸鏇窪獵廠鑰繭鏇繭) 更多 | ||||||
临床3期 | 50 | 齋廠鹹積鏇壓積窪醖夢(窪艱鑰壓膚範鏇夢簾窪) = 製顧襯繭鹽遞積憲夢範 獵糧廠膚獵選鹽鹹簾蓋 (餘壓觸網廠憲憲淵窪衊, 壓衊鹹獵製網廠鑰餘齋 ~ 構鏇齋鹽醖艱鑰鹽遞簾) 更多 | - | 2021-01-05 | |||
临床2期 | 151 | AGN-190584 Vehicle | 淵壓齋鏇鹹窪膚淵構鏇(艱鹹壓選衊構淵夢簾醖) = 繭艱顧鑰窪淵遞鬱齋鏇 膚鑰獵鏇壓膚鏇襯遞膚 (蓋壓選夢積夢窪鹽廠艱, 糧艱鹹淵顧襯餘襯鏇夢 ~ 齋壓憲淵鬱襯鹽艱齋鹹) 更多 | - | 2020-12-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用